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In vitro activation of pro-cathepsin B purified from ascitic fluid of ovarian carcinomas by serine proteinases was studied. Both elastase and cathepsin 
G from human leucocytes were found to be activators, on the basis of generation of cathepsin B activity and processing of the precursor. These 
results represent a new cooperative pathway between cancer cells and host cells. The urokinase-type plasminogen activator activated pro-cathepsin 
B faster than leucocyte proteinases. A new relationship is emerging between the cysteine proteinases and the plasmin-activation system. Both 
pathways suggest an important role of cathepsin B in the proteolytic cascade associated with tumour invasion. 
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1. INTRODUCTION 
Increased level of proteinases is generally associated 
with malignancy. Tumour cell invasion and metastasis 
require migration of malignant cells in the body follow- 
ing proteolytic digestion of basement membranes and 
extracellular matrices. Consequently, proteinases, such 
as collagenases, cathepsins, plasmin or plasminogen ac- 
tivators, could be associated with tumor spreading [l]. 
The cysteine proteinase, cathepsin B, is a lysosomal 
endopeptidase that has been implicated in tumour inva- 
sion [1,2]. Cathepsin B is secreted from human and 
murine tumours either as an active enzyme or as an 
inactive pro-enzyme. Such a distribution may result 
from altered post-translational processing and/or intra- 
cellular trafficking [2-4]. 
this same pro-enzyme by both elastase and cathepsin G 
from human leucocytes at pH 8.6 and 7.5, respectively. 
This pathway is more favourable to extracellular activa- 
tion than the aspartic proteinase pathway. Activation of 
pro-uPA by cathepsin B is known [8]. Similarly, we 
found activation of pro-cathepsin B by UPA. Both types 
of proteinases, secreted by or associated with the tu- 
mour cell surface, could be linked to abnormal proteo- 
lysis. The biological significance of pro-cathepsin B se- 
cretion may be a consequence of these reactions: gener- 
ation of active cathepsin B at near neutral pH could be 
a step in the proteolytic cascade leading to tissue de- 
struction as a prelude to tumour invasion. 
In this laboratory, we have purified a pro-cathepsin 
B from ascitic fluid of ovarian carcinomas. This pro- 
enzyme exhibited two components (45 and 36 kDa) 
which could correspond to glycosylated and non-glyco- 
sylated proforms, respectively [5,6]. Both were activata- 
ble in vitro by pepsin or cathepsin D at pH 3.0, leading 
to a 30-32 kDa cathepsin B-like proteinase, similar to 
mature single-chain lysosomal cathepsin B from normal 
tissues [7]. In this report we describe the activation of 
This is the first description of such a pathway, indi- 
cating a cooperativity between the cancer cells and the 
host cells in the generation and regulation of extracellu- 
lar proteolysis. 
2. MATERIALS AND METHODS 
2.1. Materials 
*Corresponding author. 
Trypsin, chymotrypsin, and plasmin were purchased from Boehrin- 
ger-Mannheim (Meylan, France). Elastase from human leukocytes 
and the urokinase-type plasminogen activator (uPA) from human 
urine were provided by Serva (St. Germain en laye, France). Cathepsin 
G from human leukocytes and the fluorogenic substrate, Z-Arg-Arg- 
NHMEC, were obtained from Nova-Biochem (Laufeltingen, Switzer- 
land). Nitrocellulose sheets were from Schleicher and Schtill (Dassel, 
Germany). 
Abbreviurions: cathepsin B, EC 3.4.22.1; elastase, EC 3.4.21.11; Fluorescence measurements were carried out on a Kontron SFM 
cathepsin G, EC 3.4.21.20; urokinase, uPA, EC 3.4.21.31; Z, ben- 25 spectrofluorometer at 2, 347 nm and ;I, 440 nm using NH,Mec 
zyloxycarbonyl; NH-Met, 4 methyl-7-coumarylamide; EDTA, ethyl- for calibration. Electrophoresis was carried out using a vertical tank 
ene diamine tetraacetate, disodium salt; DTE, dithioetythritol; PBS, (G&co-BRL, Cergy-Pontoise, France). Immunoblotting was carried 
phosphate buffer saline. out using a Novablot transfer-kit from LKB (Les Ulis, France). 
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2.2. Activation of pro-cathepsin B by serme proteinases 
Pro-cathepsin B was purified from malignant as&tic fluid as de- 
scribed before [5]. In each experiment, approximately 20 fig of purified 
precursors were incubated at different imes (O-150 min) with 5 pug of 
one of the following serine proteinases: trypsin, chymotrypsin, plas- 
min, leukocyte lastase, leukocyte cathepsin G, or uPA. Alternatively, 
1 or 2pg of each serine proteinases was checked. The following buffers 
were used: 100 mM Tris-HCl, pH 8.0, containing 100 mM NaCl for 
trypsin; 50 mM Tris-HCl, pH 8.0, containing 100 mM NaCl for 
chymotrypsin; 50 mM Tris-HCl, pH 8.6, containing 100 mM NaCl for 
elastase; and phosphate-buffered saline (PBS) 100 mM, pH 7.4, con- 
taining 150 mM NaCl, for cathepsin G, plasmin, and uPA. The activa- 
tion step was performed in 100 ~1 final volume. Cathepsin B activity 
was thereafter measured by adding 400 ~1 of phosphate buffer 100 
mM, pH 6.8, containing 1 mM DTE, 2 mM EDTA, together with 10 
91 Z-Arg-Arg-NHMec (10 mM, stock solution). The reaction was 
stopped by the addition of 100 ~1 monochloroacetate, pH 4.3, after 
30 min of incubation. Fluorescence of the reaction product was meas- 
ured as described above. For each proteinase, a control experiment 
was carried out with pro-cathepsin B alone, which was subtracted 
from the final value. 
2.3. Immunoblotting 
Slab gel-electrophoresis (15%) in the presence of SDS with reduc- 
tion (10 mM DTE) was performed according to the method of 
Laemmli [9]. Proteins were transferred electrophoretically onto nitro- 
cellulose sheets. Following protein transfer, blots were treated with 
anti-cathepsin B antibodies as described previously [4,5]. 
3. RESULTS AND DISCUSSION 
As shown in Figs. 1A and 2A, elastase cathepsin G 
250 1 A 
and urokinase were able to activate pro-cathepsin B 
leading to active cathepsin B-like proteinase. The extent 
of autoactivation was the following: 10% after a 120 
min incubation at pH 8.6; 5--10% for the different incu- 
bation times at pH 7.4. Consequently, in this pH range, 
the autoactivation seems to be irrelevant. Chymotrypsin 
gave little cathepsin B activity and neither plasmin nor 
trypsin activated the pro-enzyme (data not shown). 
Nevertheless, in both cases, the time dependency of this 
activation was different: leucocyte elastase and cathep- 
sin G gave a maximal cathepsin B activity after a 120 
min incubation. On the contrary, UPA activated pro- 
cathepsin B more quickly (lo-30 min), followed by a 
fast decrease of enzymatic activity (Fig. 2A). This acti- 
vation was associated with the processing of the pro- 
enzymes (45-36 kDa) into two chain-forms of cathepsin 
B, as demonstrated by immunoblotting using antibodies 
directed against human liver cathepsin B. The process- 
ing with elastase, cathepsin G and urokinase showed the 
same temporal pattern as the appearance of cathepsin 
B activity, i.e. the pro-enzymes were fully processed 
after 120 min with elastase or cathepsin G, and after 
only 10 min with urokinase (Figs. 1B and 2B). The 
molar ratios of pro-cathepsin B vs. UPA and of pro- 
cathepsin B vs. elastase or cathepsin G were about 5 and 
3, respectively. When we used 1 or 2 ,ug of activating 
proteinases, no significant activation was found. On the 
M kDa 
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Fig. 1. (A) Generation of cathepsin B from purified pro-cathepsin B as a function of time. Approximatively 20 fig (20 ~1) of purified precursor 
was incubated with 5 fig (5 ~1) of leucocyte lastase or cathepsin G in 100 ,uI (final volume) of 50 mM Tris-HCl buffer, pH 8.6, containing 150 
mM NaCl for leucocyte lastase and cathepsin G, respectively. The following incubation times were used: 0, 15, 30, 60, 120, and 150 min. The 
cathepsin B activity was measured by adding 390 ,~l of 100 mM phosphate buffer, pH 6.8, containing 1 mM DTE, 2 mM EDTA, 10 ~1 
Z-Arg-Arg-NHMec. After 30 min incubation time, the fluorescence of free NH,Mec was measured. Activation by elastase (a) and cathepsin G 
(+), respectively. (B) Processing of pro-cathepsin B as a function of time studied by the immunoblotting procedure. After incubation as in A the 
samples were boiled for 5 min at 95°C with 30 ~1 of 10% SDS/30% glycerol, followed by 15% SDS- PAGE, and transferred to a nitrocellulose sheet 
(2 h, 300 mA). The sheet was blocked with 2% BSA in PBS overnight. Immunological staining was performed with anti-cathepsin B polyclonal 
antibodies (40 @g/ml), anti-sheep biotinylated immunoglobulins (2 &ml), extravidin (2 &ml) and biotin horseradish peroxidase (2 &ml). The 
bands were visualized using 4-chloro-1-naphtol. Lanes 14, processing with leucocyte lastase, incubation times 0,30,60,120 min; lane 5, prestained 
BRL standard proteins; lanes 69, processing with cathepsin G. Incubation times 0, 30, 60, 120 min. 
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other hand, chymotrypsin processed the pro-enzymes 
partially, trypsin digested the pro-enzymes, and plasmin 
had no effect on the processing of pro-enzymes (data 
not shown). Pro-cathepsin B is secreted by several trans- 
formed cells, including cultured colonic and breast cells 
[4, lo]. Consequently, high concentrations of pro- 
cathepsin B have been found in ascitic fluids from ovar- 
ian carcinomas [5,6]. 
Recently, a similar pro-enzyme has been purified 
using ascitic fluids from colon cancer [l 11. All studies 
reported the presence of latent cathepsin B-like species. 
The in vivo significance of such pro-enzymes could de- 
pend on the presence of different activation pathways. 
Intracellularly, the aspartyl proteinase pathway could 
be the most important one [12]. Nevertheless, this path- 
way would be associated with digestion of basement 
membrane in large acidic vesicles of breast cancer cells 
[13]. Using a yeast expression system for recombinant 
rat pro-cathepsin B, activation by cysteine proteinases, 
such as cathepsins B and L, was found. Processing sites 
of leucocyte elastase, cathepsin D, pepsin and cathep- 
sins B and L have been identified by means of active site 
mutants of pro-cathepsin B. However, generation of 
active cathepsin B from the mutant form was impossible 
[14]. Results on the activation of pro-cathepsin B by 
leucocyte elastase from human sputum have been previ- 
ously reported [ 151. In the present report, both leucocyte 
serine proteinases, located in the azurophil granules, 
80 -I A 
activated pro-cathepsin B following a time-dependent 
lag phase for the generation of the enzymatic activity 
and the processing. Elastase was a better activator than 
cathepsin G on the basis of the activation curves. Other 
serine proteinases, such as trypsin or chymotrypsin, ac- 
tive in the same pH range, did not activate pro-cathep- 
sin B significantly. From these observations, a leucocyte 
activation pathway can be postulated. Such a pathway 
could generate cathepsin B locally around tumour islets, 
following inflammation and invasion by leucocytes as- 
sociated with many cancers [l]. These cells are able to 
liberate elastase and cathepsin G which are active at 
neutral pH. Both proteinases generate cathepsin B ac- 
tive at near neutral pH, and this could contribute to the 
invasion through digestion of basement membranes and 
extracellular matrices [16]. 
On the other hand, we have studied the action of UPA 
and plasmin on pro-cathepsin B: only UPA was able to 
generate enzymatic activity and to process pro-cathep- 
sin B. Plasmin had no effect at either level. The activa- 
tion and the processing were faster with UPA than with 
leucocyte proteinases. Another pathway, the activation 
of soluble and bound Pro-uPA by cathepsin B, has also 
been described [8]. These pathways could function syn- 
ergystically, leading to an increased level of both pro- 
teinases. The activations occurred at the same time, i.e. 
the UPA activity generated from pro-uPA with cathep- 
sin B reached a maximum after 30 min [8], and the 
M kDa 
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Fig. 2. (A) Generation of cathepsin B from purified pro-cathepsin B as a function of time. Approximatively 20 pg (20 ~1) of purified precursor 
was incubated with 5 pg (5 ~1) of uPA in 100 ~1 (final volume) of 100 mM PBS, pH 7.4, containing 150 mM NaCl. The following incubation times 
were used: 0, 2, 5, 8, 10, 12, 15 min. The cathepsin B activity was thereafter measured by adding 390 ~1 of 100 mM phosphate buffer, pH 6.8, 
containing 1 mM DTE, 2 mM EDTA, 10 ~1 Z-Arg-Arg-NHMec. After 30 min incubation, the fluorescence of free NH,Mec was measured. 
(B) Processing of pro-cathepsin B as a function of time studied by the immunoblotting procedure. After incubation as in A the samples were boiled 
for 5 min at 95°C with 30 ~1 of 10% SDS/30% glycerol, followed by 15% SDS-PAGE and transfered to a nitrocellulose sheet (2 h, 300 mA). The 
sheet was blocked by 2% BSA in PBS overnight. Immunological staining was performed with anti-cathepsin B polyclonal antibodies (40 &ml), 
anti-sheep biotinyled immunoglobulins (2&ml), extravidin (2&ml) and biotin horseradish peroxidase (2&ml). The bands were vizualized using 
4-chloro-1-naphtol. Lane 1, prestained BRL standards proteins; lanes 2-5, processing with uPA, incubation times 0, 5, 10, 15 min. 
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cathepsin B activity generated from pro-cathepsin B 
with UPA was maximum after about 10 min (Fig. 2A). 
Expression of both UPA and cathepsin B on the cell 
surface of HOC1 ovarian cancer cells has been reported 
[17]. Both proteinases were implicated in the invasive 
capacity of these cells. This could be, at the cellular 
level, an illustration of the activation pathways de- 
scribed. Activation of pro-uPA by the cysteine pro- 
teinase, cathepsin L, has been shown [18]. A strong 
relationship between the cysteine proteinases and the 
plasmin pathway is emerging, which could be important 
in malignancy, both on the basis of increased levels of 
these components and reciprocal activation mecha- 
nisms. A significant direct degradation of basement 
membrane type IV collagen by plasmin has been found 
[19]. Such a result stresses the involvement of a prote- 
olytic cascade dependent on cysteine proteinases in tu- 
mour invasion. 
Rowan et al. have found that the processing of pro- 
cathepsin B is a consequence of a peptide bond cleavage 
in a very short region of the pro-peptide (amino acids 
-9 to -4): elastase, cathepsin D, pepsin, cathepsins B 
and L. and papain cleaved and activated pro-cathepsin 
B in this region [14]. We have noticed the presence of 
the Arg-Val bond (-9 to -8) which corresponds to the 
specificity of uPA, suggesting activation of the pro- 
cathepsin B by UPA at this site. Similarly, cathepsin G, 
which is a chymotrypsin-like proteinase, could activate 
pro-cathepsin B by hydrolysing the Phe-Ser bond (-6 
to -5). Thus, the different activation pathways of pro- 
cathepsin B are dependent on the short sequence of this 
pro-peptide which could be a hinge region located be- 
tween the pro-peptide and the active proteinase. 
In conclusion, as a consequence of the gene over- 
expression [20], pro-cathepsin B is synthetized in excess 
and secreted by a lot of human cancer cells. Generation 
of extracellularly active cathepsin B is dependent on 
serine proteinases, such as leucocyte elastase, cathepsin 
G and uPA. These new activation pathways give a more 
important biological significance to pro-cathepsin B in 
the proteolytic process associated with tumour inva- 
sion. 
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